Akt inhibitors, a course of second\series therapeutic medications under analysis for treating HCC in clinical studies, enhanced the consequences of sorafenib, but activated the c\Met pathway in sorafenib\resistant cells also
Akt inhibitors, a course of second\series therapeutic medications under analysis for treating HCC in clinical studies, enhanced the consequences of sorafenib, but activated the c\Met pathway in sorafenib\resistant cells also.…